These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23038762)

  • 1. Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data.
    Lintermans A; Laenen A; Van Calster B; Van Hoydonck M; Pans S; Verhaeghe J; Westhovens R; Henry NL; Wildiers H; Paridaens R; Dieudonné AS; Leunen K; Morales L; Verschueren K; Timmerman D; De Smet L; Vergote I; Christiaens MR; Neven P
    Ann Oncol; 2013 Feb; 24(2):350-355. PubMed ID: 23038762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome.
    Morales L; Pans S; Verschueren K; Van Calster B; Paridaens R; Westhovens R; Timmerman D; De Smet L; Vergote I; Christiaens MR; Neven P
    J Clin Oncol; 2008 Jul; 26(19):3147-52. PubMed ID: 18474874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
    Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
    Lintermans A; Van Calster B; Van Hoydonck M; Pans S; Verhaeghe J; Westhovens R; Henry NL; Wildiers H; Paridaens R; Dieudonné AS; Leunen K; Morales L; Verschueren K; Timmerman D; De Smet L; Vergote I; Christiaens MR; Neven P
    Ann Oncol; 2011 Aug; 22(8):1763-9. PubMed ID: 21273342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
    Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P
    Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study.
    Singer O; Cigler T; Moore AB; Levine AB; Hentel K; Belfi L; Do HT; Mandl LA
    Arthritis Care Res (Hoboken); 2012 Dec; 64(12):1910-8. PubMed ID: 22730307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography.
    Henry NL; Jacobson JA; Banerjee M; Hayden J; Smerage JB; Van Poznak C; Storniolo AM; Stearns V; Hayes DF
    Cancer; 2010 Sep; 116(18):4360-7. PubMed ID: 20549827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
    Roberts KE; Adsett IT; Rickett K; Conroy SM; Chatfield MD; Woodward NE
    Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013167. PubMed ID: 35005781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
    Roberts KE; Rickett K; Feng S; Vagenas D; Woodward NE
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012988. PubMed ID: 31994181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation.
    Henry NL; Speth K; Lintermans A; Kidwell KM; Carlson R; Hayes DF; Neven P
    Clin Breast Cancer; 2017 Aug; 17(5):350-355.e4. PubMed ID: 28365336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant endocrine therapy for postmenopausal women: Type and duration.
    Mayer EL; Burstein HJ
    Breast; 2015 Nov; 24 Suppl 2():S126-8. PubMed ID: 26279133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients.
    Morales L; Timmerman D; Neven P; Konstantinovic ML; Carbonez A; Van Huffel S; Ameye L; Weltens C; Christiaens MR; Vergote I; Paridaens R
    Ann Oncol; 2005 Jan; 16(1):70-4. PubMed ID: 15598941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients.
    Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
    Breast Cancer Res Treat; 2009 Jan; 113(2):321-6. PubMed ID: 18297393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Grip Strength in Women Being Treated for Breast Cancer and Receiving Adjuvant Endocrine Therapy: Systematic Review.
    Van der Weijden-Van Doornik EM; Slot DE; Burtin C; van der Weijden GA
    Phys Ther; 2017 Sep; 97(9):904-914. PubMed ID: 28969348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of arthralgia with estrogen deprivation.
    Lintermans A; Neven P
    Steroids; 2011 Jul; 76(8):781-5. PubMed ID: 21377484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.
    Sheng JY; Blackford AL; Bardia A; Venkat R; Rosson G; Giles J; Hayes DF; Jeter SC; Zhang Z; Hayden J; Nguyen A; Storniolo AM; Tarpinian K; Henry NL; Stearns V
    Breast Cancer Res Treat; 2019 Aug; 176(3):617-624. PubMed ID: 31079282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK; Nielsen DL; Lindberg H; Kamby C
    Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.